Plerixafor as First- and Second-Line Strategies for Autologous Stem Cell Mobilization in Patients with Non-Hodgkin's Lymphoma or Multiple Myeloma

2012 ◽  
Vol 32 (7) ◽  
pp. 596-603 ◽  
Author(s):  
Kevin W. Lor ◽  
Pieter J. Helmons ◽  
Helen Belew ◽  
James R. Lane ◽  
Edward D. Ball
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Hodgkin’S Lymphoma ◽  
Stem Cell Mobilization ◽  
Hodgkin's Lymphoma ◽  
Second Line ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Cell Mobilization

Intensive Dose Ifosfamide and Etoposide with G-CSF for Stem Cell Mobilization in Patients with Non-Hodgkin's Lymphoma

1999 ◽  
Vol 35 (3-4) ◽  
pp. 317-324 ◽  
Author(s):  
M. L. Donato ◽  
R. E. Champlin ◽  
K. W. van Besien ◽  
M. Korbling ◽  
F. Cabanillas ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hodgkin’S Lymphoma ◽  
Stem Cell Mobilization ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Cell Mobilization

Effects of Pretransplantation Treatment With Rituximab on Outcomes of Autologous Stem-Cell Transplantation for Non-Hodgkin's Lymphoma

2004 ◽  
Vol 22 (22) ◽  
pp. 4561-4566 ◽  
Author(s):  
Amy L. Hoerr ◽  
Feng Gao ◽  
Josephine Hidalgo ◽  
Divya Tiwari ◽  
Kristie A. Blum ◽  
...  
Keyword(s):  
Overall Survival ◽  
Stem Cell ◽  
Hodgkin’S Lymphoma ◽  
Stem Cell Mobilization ◽  
Hodgkin's Lymphoma ◽  
Post Transplantation ◽  
Intermediate Grade ◽  
Non Hodgkin's Lymphoma ◽  
Cell Mobilization ◽  
Disease Free

Purpose To analyze the effects of preautografting treatment with rituximab (R) on stem-cell mobilization, post-transplantation complications, engraftment, disease-free survival, and overall survival in patients with non-Hodgkin's lymphoma (NHL). Patients and Methods Single-institution retrospective comparative outcome analysis in a cohort of 273 relapsed chemosensitive NHL patients of whom 127 (47%) received R pretransplantation. Results R was administered a median of 3 months before autologous transplantation. When compared to the nonrituximab group, R patients were older (56 v 50 years; P < .001), and had delays in post-transplantation platelets recovery (39 v 27 days; P = .001). Pretransplantation R did not affect stem-cell mobilization, post-transplantation early complications, duration of hospitalization, or mortality rates at days 30 and 100. In contrast to patients with low-grade NHL, both disease-free and overall survival rates were significantly better when R was included in the pretransplantation salvage therapy for patients with intermediate-grade NHL. Conclusion In this large, single-center retrospective analysis, pretransplantation treatment with R was associated with improved survival in patients with intermediate-grade NHL, at the price, however, of a delay in platelet engraftment.

Sign in / Sign up

Export Citation Format

Share Document